Compugen initiated with a Buy at EF Hutton

EF Hutton analyst Tony Butler initiated coverage of Compugen with a Buy rating and $13 price target. The clinical-stage biotech has an immune-oncology pipeline consisting of three clinical programs targeting immune checkpoints and the lead program, COM701, has shown utility as monotherapy and in combination with other checkpoint inhibitors, Butler tells investors.